Fellow in Cornea and External Diseases, Aravind Eye Hospitals and Post Graduate Institute, Tirunelveli, Tamil Nadu, India.
HOD, Cornea and Refractive Services, Aravind Eye Hospitals and Post Graduate Institute, Tirunelveli, Tamil Nadu, India.
Indian J Ophthalmol. 2020 Dec;68(12):3006-3011. doi: 10.4103/ijo.IJO_1492_20.
: The aim of this study was to evaluate the safety, efficacy, and complications of V4c Toric implantable collamer Lens (TICL) implantation for myopic astigmatism in the south Indian population.
In this retrospective observational case series, a total of 109 eyes of 67 patients who underwent V4c TICL implantation (ICL, V4C Staar Surgical, Nidau, Switzerland) between January 2012 and August 2019 were studied with a minimum follow-up period of 6 months (mean 24 months). The main outcome measures were objective and subjective refraction, uncorrected distance visual acuity, corrected distance visual acuity (CDVA), safety, predictability, adverse events, and postoperative complications.
At 6 months, mean manifest refractive spherical equivalent (SE) decreased from -10.90 ± 3.7D preoperatively to -0.02 ± 0.13D postoperatively (P < 0.001) and mean cylinder decreased from -2.3 ± 1.3 D preoperatively to -0.04 ± 0.2 D postoperatively (P < 0.001). Postoperatively, SE within ± 0.5 D and ± 1.0 D of attempted correction were achieved in 96.3 (105 eyes) and 100% (109 eyes), respectively. Manifest refractive cylinder within ± 0.5 D and ± 1.0 D of attempted correction were achieved in 97.2 (106 eyes) and 100% (109 eyes), respectively. Sixty-two percent (68 eyes) showed no change in CDVA postoperatively, and no eye had lost lines of CDVA. The safety index was 1.12, and the efficacy index was 1.10. Complications were seen in two eyes (1.8%) due to high postoperative vault requiring secondary surgical interventions.
V4c TICL is a highly effective, safe, and predictable option in treating myopic astigmatism with excellent improvement in vision and spectacle independence.
本研究旨在评估 V4c Toric 可植入 Collamer 透镜(TICL)在印度南部人群治疗近视散光的安全性、有效性和并发症。
在这项回顾性观察性病例系列研究中,共对 67 例 109 只眼(ICL,V4C Staar Surgical,Nidau,瑞士)接受 V4c TICL 植入术(ICL,V4C Staar Surgical,Nidau,瑞士)的患者进行了研究,这些患者的随访时间至少为 6 个月(平均 24 个月)。主要观察指标包括客观和主观屈光、未矫正远视力、矫正远视力(CDVA)、安全性、可预测性、不良事件和术后并发症。
术后 6 个月,平均显微微观屈光等效球镜(SE)从术前的-10.90 ± 3.7D 降低至术后的-0.02 ± 0.13D(P < 0.001),平均柱镜从术前的-2.3 ± 1.3D 降低至术后的-0.04 ± 0.2D(P < 0.001)。术后,96.3%(105 只眼)和 100%(109 只眼)的 SE 达到了± 0.5D 和± 1.0D 的目标矫正值。97.2%(106 只眼)和 100%(109 只眼)的显示屈光柱镜达到了± 0.5D 和± 1.0D 的目标矫正值。术后 62%(68 只眼)的 CDVA 无变化,无眼视力下降。安全性指数为 1.12,有效性指数为 1.10。由于术后高拱顶,有两例(1.8%)眼需要二次手术干预,出现并发症。
V4c TICL 是治疗近视散光的一种高度有效、安全和可预测的选择,可显著改善视力和提高脱镜率。